LUTHERVILLE, MD, March 20, 2017 – AgriMetis, LLC is pleased to announce that the first international patent applications covering its insecticide portfolio of novel spinosyns have published.AgriMetis has validated its ability to discover and develop new innovative agricultural chemical molecules by applying a biopharmaceutical research model. “The novel compounds described in these first published applications show improved efficacy compared to previously known spinosyn analogs. AgriMetis’ combination of biology and chemistry has allowed it to develop differentiated compounds in a well studied chemical space,” said Brian Green, AgriMetis’ VP of Research and Development.With its recent Series B Preferred Stock financing, AgriMetis is positioned to deliver commercially viable products to the agricultural crop protection industry while continuing to progress its research and development pipeline.“This was a critical milestone and validation for the AgriMetis team,” said Steven Tuttle, President and CEO of AgriMetis. “We are excited to transition into active business development to provide new innovative technology to the global agricultural chemical channel partners,” Tuttle added.For more information on the specific PCT publications, links are provided below:https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017040878https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017040769https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017040882https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017040763

About AgriMetis:

In an evolving and growing global population, there continues to be an increasing demand for sustainable, crop protection products. AgriMetis is dedicated to fulfilling this need. Our mission is to innovate sustainable crop protection products through leading edge and advanced discovery, development and delivery methods.The AgriMetis technology platform is at the interface of biology, biochemistry, and chemistry. AgriMetis’ scientific approach is multidisciplinary and integrated, which allows AgriMetis to exploit areas of chemical space and production routes that are inaccessible to others.AgriMetis was formed in March 2014 and completed a Series B financing in December 2016 to fund agriculture chemical research and development by applying a biopharmaceutical model. With headquarters near Baltimore, Maryland, AgriMetis continues to grow and develop its technologies and capabilities.For more information, please visit our website at http://www.agrimetis.com.Contact:Steven Tuttle, President & CEOAgriMetis, LLC10751 Falls Road, Suite 300Lutherville, MD 20193Source: http://www.agrimetis.com/blog-posts/2017/3/20/agrimetis-announces-publication-of-spinosyn-analog-patent-applications